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Introduction: New drugs against multi-(MDR) and extensively drug (XDR) resistant tubercu-
losis are urgently needed. While new candidate drugs are being developed, reinvestigation
of already approved drugs available for other indications could be of value. The objective of
this study is to determine tentative drug susceptibility testing strategies and breakpoints
for thioridazine, a well-known and well-tolerated neuroleptic drug, which has been shown
to be effective against drug resistant tuberculosis both in vitro and in vivo.
Methods: By testing the minimal inhibitory concentration (MIC) on Middlebrook 7H10
media, the wild-type distribution of thioridazine was established forMycobacterium tubercu-
losis (n = 51) and this distribution was compared to the MICs of M/XDR strains (n = 67).
Results: A tentative epidemiological cut off (ECOFF) of thioridazine at 16 mg/L was sug-
gested. Even though such concentrations are not clinically achievable in serum, thiorida-
zine is concentrated intracellularly and concentrations of only 0.1 mg/L has been shown
to kill M. tuberculosis residing inside cells. MICs above the wild-type (MIC > 16 mg/L) were
found in 4/67 (6%) of the M/XDR strains suggesting that resistance mechanisms against thi-
oridazine may already be present in resistant clinical strains.
Conclusions: In view of the difficulties obtaining clinical outcome data for single drugs in
the case of tuberculosis since combination therapy is mandatory, the tentative ECOFF
may be considered a tentative clinical breakpoint, but the findings should be validated
by others. The data from this study strengthens the use of thioridazine as a treatment
option for M/XDR tuberculosis, although its proper place in the therapeutic arsenal should
ideally be confirmed in clinical trials.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
The alarming increase of multidrug resistant (MDR) and
extensively drug resistant (XDR) tuberculosis (TB) has not
been matched by the development of new anti-TB drugs. Re--African Society for Myco
ent of Clinical Microbi
99.
ka.se (K. A¨ngeby).cently, it has been suggested that the neuroleptic drug thio-
ridazine may take a place in the therapeutic arsenal [1].
Thioridazine has been used safely for the treatment of
psychiatric disorders for more than 40 years and has shownbacteriology. All rights reserved.
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men) activity against Mycobacterium tuberculosis [1–3].
Severalmodes of action have been described, such as inter-
action with bacterial respiration, blocking of calcium binding
to proteins, e.g., calcium-dependent ATPases, as well as cell
wall damage through a hitherto unidentified mechanism [4].
Inhibition of efflux pump activity has also been shown. For
example, thioridazine can block the ethidium bromide efflux
activity, which is correlated to the efflux of several antibiotics
[5]. This may explain that a synergistic effect of thioridazine
together with standard anti-TB drugs such as pyrazinamide
and rifampicin has been shown in vitro and in vivo (mice)
[1,3]. Since the antimicrobial activity of thioridazine involves
different pathways, it has been speculated that resistance ow-
ing to single-step mutations is unlikely. Nevertheless, if thio-
ridazine is introduced for widespread use in M/XDR-TB
patients, previous experience suggests that drug resistance
might also eventually occur to this drug. However, as far as
this study is concerned, appropriate antimicrobial susceptibil-
ity testing (AST) methods have not been defined and a break-
point towhich AST should be related has not been established.
For other bacterial and fungal pathogens, the setting of
breakpoints for AST is based on the establishment of wild-
type minimum inhibitory concentrations (MICs) in combina-
tion with pharmacokinetic and pharmacodynamic (PK/PD)
information, as well as clinical outcome data as recom-
mended by, e.g., the EUCAST (www.eucast.org). The wild-type
distribution of MICs is defined by testing the MICs for a large
number of consecutive ‘‘wild type’’ strains. The MICs form
(with few exceptions) a normal (Gaussian) distribution, and
the highest MIC in the wild-type distribution has been labeled
the epidemiological cut off or ECOFF. Strains with MICs above
the ECOFF are likely to harbor acquired mutational resistance
mechanisms. For TB, combination therapy is the rule, and
clinical and PD data for individual drugs is therefore difficult
to obtain, and in such cases, susceptibility testing breakpoints
will have to rely mainly on wild-type MIC distributions and
ECOFFs [6]. Even though this concept has not been widely
used for TB, the authors of this study have recently published
wild-type MIC distributions and tentative ECOFFs for both
first- and second-line anti TB drugs [7–12].
The aim of the present study is to suggest a tentative break-
point for testing the susceptibility ofM. tuberculosis to thiorida-
zine by: (i) establishing the wild-type MIC distribution of
thioridazine for M. tuberculosis; and (ii) comparing the MICs of
wild-typeM. tuberculosis strains to the MICs of M/XDR strains.Fig. 1 – MIC distributions of consecutive (wild-type, green),
MDR (orange), XDR (red), and other non-consecutive strains.
The highest MIC within the wild-type i.e. the tentative
epidemiological cut off (ECOFF) is indicated by an arrow.
Strains with MICs above the ECOFF may harbor resistance
mechanisms.Materials and methods
Strains
To determine the wild-type MIC distribution for thioridazine,
51 consecutive clinical M. tuberculosis strains from the myco-
bacteriology laboratory at Karolinska University Hospital in
Stockholm, Sweden, were tested. Moreover, 100 non-consecu-
tive strainswere tested from the strain collection at the Swed-
ish Institute for Infectious Disease Control (SMI). Among
these strains, 67 were MDR, including 16 XDR, and the
remaining 33 exhibited other resistance patterns or were sus-ceptible to anti TB drugs as previously determined by the Bac-
tec 460 or 960 methods or the proportion method on
Middlebrook 7H10 media.
MIC determinations
MIC determinations were performed in two different rounds
as described in detail previously [7]. Shortly, by the use of a
96-stick replicator, bacterial suspensions were inoculated
onto 14-cm petri dishes containing Middlebrook 7H10 agar
medium and thioridazine (Sigma) in a 2-fold serial dilution
ranging from 0.002 to 512 mg/L. The plates were incubated
at 37 C for three weeks and then read visually by comparing
the growth for each strain with a 1:100 diluted growth control.
The MIC was determined as the lowest concentration with
less growth than the 1:100 diluted control, hence representing
>99% inhibition. The pan-susceptible M. tuberculosis control
strain H37Rv was tested in duplicate in both rounds.
Results and discussion
The MIC of thioridazine for M. tuberculosis H37Rv was consis-
tently 8 mg/L, which indicates excellent intra- and inter-assay
reproducibility. Out of 51 consecutive clinical M. tuberculosis
strains, 48 had an MIC of 8 mg/L and three had an MIC of
16 mg/L, thus showing an unusually narrow wild-type MIC
distribution with an ECOFF of 16 mg/L (Fig. 1). Similar MIC
range (8–32 mg/L) has also been reported previously by using
the Bactec 460 method for 13 M. tuberculosis strains showing
various resistance patterns [2]. Using the absolute concentra-
tion method, van Ingen et al. obtained thioridazine MICs of
4 mg/L for eight M. tuberculosis strains regardless of their sus-
ceptibility to other anti TB drugs [2].
Thioridazine has been shown to effectively kill drug sensi-
tive and MDR-TB in mice [3] and to cure 10/12 untreatable
XDR-TB patients with a daily dosage of 75 mg as compassion-
ate therapy [1]. However, the clinical effect of the drug in com-
parison and in combination with the other drugs which are
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als are under way, and if these results are also favorable, it
seems plausible that thewild-type strains are possible to treat
with therapeutic dosages.
The MICs of 67 M/XDR strains, as well as 33 other non-con-
secutive strains were in the same range as the wild-type (4–
16 mg/L). One MDR and three XDR strains displayed MICs of
32 mg/L, i.e., above the ECOFF. Even if wild-type strains could
be treated with normal dosages (i.e., 75 mg/day), this is not
necessarily true for strains with MICs above the ECOFF, which
could have resistance mechanisms. These mechanisms could
be general, i.e., affecting different drug classes, and one pos-
sible explanation is that these M/XDR strains during anti-TB
therapy have gained an increased efflux pump activity [13]
in order to decrease the level of antibiotics from the cell and
that these efflux pumps also affect thioridazine (even though
thioridazine itself is an efflux pump inhibitor), but this re-
mains speculative and has to be proven. However, it is still
interesting to note that, irrespective of the mechanism, resis-
tance to thioridazine is likely to occur and may even already
be present among highly resistant strains. Thus, thioridazine
needs to be introduced with great care in combination with
other drugs effective against M. tuberculosis in order to avoid
the selection of drug-resistant mutants.
Serum concentrations at similar level as the wild-type
MICs are not possible to achieve in humans in vivo, mainly ow-
ing to a dose-dependent risk of prolonged QT interval and se-
vere ventricular arrhythmias [4]. The risk of cardiac toxicity
was observed in psychiatric patients and typically when daily
doses of more than 800 mg/day were given [4]. However, ser-
um concentrations of 0.5–1 mg/L are fully achievable, and it
has been shown that thioridazine is concentrated at least
10-fold inside the vacuoles of themacrophage, i.e., the natural
habitat ofM. tuberculosis, and that even the low concentration
of 0.1 mg/L can kill intracellular M. Tuberculosis [2,4].
In conclusion, serum concentrations of thioridazine can-
not be compared directly with the obtained MICs of the
wild-type strains to predict the killing of M tuberculosis
in vivo, but an MIC above the ECOFF (i.e., above the wild-type
MICs) could indicate the presence of acquired resistance
mechanisms. A tentative ECOFF of 16 mg/L for drug suscepti-
bility testing on Middlebrook 7H10 medium is suggested to
differ between wild-type and non wild-type strains. The EC-
OFF may serve as a tentative clinical breakpoint, but more
clinical data is needed. The findings of this study need to be
confirmed by other investigators. Although the results are
promising, more clinical studies, ideally randomised con-
trolled trials arewarranted to determine the exact role for thi-
oridazine in the treatment of TB.
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